Reported 24 days ago
Novartis CEO Vas Narasimhan expressed strong confidence in achieving at least 5% annual sales growth through 2028, despite upcoming patent expirations on some medications. He emphasized that the company has a robust pipeline of multi-billion dollar drugs and plans to maintain a core operating profit margin around 40%. Narasimhan also mentioned the potential for acquisitions, primarily focusing on smaller deals.
Source: YAHOO